451 related articles for article (PubMed ID: 29024564)
1. Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity.
Jiang YH; Jhang JF; Chen SF; Kuo HC
Low Urin Tract Symptoms; 2019 Jan; 11(1):66-71. PubMed ID: 29024564
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Effects of Botulinum Toxin A, via Urethral Sphincter Injection on Voiding Dysfunction Due to Different Bladder and Urethral Sphincter Dysfunctions.
Lee YK; Kuo HC
Toxins (Basel); 2019 Aug; 11(9):. PubMed ID: 31450851
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity.
Jiang YH; Chen SF; Jhang JF; Kuo HC
Neurourol Urodyn; 2018 Nov; 37(8):2651-2657. PubMed ID: 29797345
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic outcome of active management in male patients with detrusor underactivity based on clinical diagnosis and videourodynamic classification.
Lee CL; Jhang JF; Ho HC; Jiang YH; Hsu YH; Kuo HC
Sci Rep; 2022 Jan; 12(1):362. PubMed ID: 35013465
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Effects of Urethral Sphincter Botulinum Toxin A Injection on Dysfunctional Voiding with Different Videourodynamic Characteristics in Non-Neurogenic Women.
Jiang YH; Lee CL; Chen SF; Kuo HC
Toxins (Basel); 2021 May; 13(5):. PubMed ID: 34069448
[TBL] [Abstract][Full Text] [Related]
6. OnabotulinumtoxinA Urethral Sphincter Injection as Treatment for Non-neurogenic Voiding Dysfunction - A Randomized, Double-Blind, Placebo-Controlled Study.
Jiang YH; Wang CC; Kuo HC
Sci Rep; 2016 Dec; 6():38905. PubMed ID: 27958325
[TBL] [Abstract][Full Text] [Related]
7. Open-label study evaluating outpatient urethral sphincter injections of onabotulinumtoxinA to treat women with urinary retention due to a primary disorder of sphincter relaxation (Fowler's syndrome).
Panicker JN; Seth JH; Khan S; Gonzales G; Haslam C; Kessler TM; Fowler CJ
BJU Int; 2016 May; 117(5):809-13. PubMed ID: 26435296
[TBL] [Abstract][Full Text] [Related]
8. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment.
Alloussi SH; Lang Ch; Eichel R; Al-Kaabneh A; Seibold J; Schwentner C; Alloussi S
World J Urol; 2012 Jun; 30(3):367-73. PubMed ID: 21842216
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of urethral injection of botulinum A toxin in the treatment of voiding dysfunction after radical hysterectomy.
Kuo HC
Urol Int; 2005; 75(3):247-51. PubMed ID: 16215314
[TBL] [Abstract][Full Text] [Related]
10. Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries.
Kuo HC; Liu SH
Neurourol Urodyn; 2011 Nov; 30(8):1541-5. PubMed ID: 21717505
[TBL] [Abstract][Full Text] [Related]
11. Video-urodynamic characteristics of non-neurogenic, idiopathic underactive bladder in men - A comparison of men with normal tracing and bladder outlet obstruction.
Jiang YH; Kuo HC
PLoS One; 2017; 12(4):e0174593. PubMed ID: 28376105
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes of detrusor underactivity in women based on clinical and videourodynamic characteristics.
Chen SF; Jhang JF; Jiang YH; Kuo HC
Int Urol Nephrol; 2022 Jun; 54(6):1215-1223. PubMed ID: 35294677
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
Chen YC; Kuo HC
Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
[TBL] [Abstract][Full Text] [Related]
14. Neurogenic failures of the external urethral sphincter closure and relaxation; a videourodynamic study.
Sakakibara R; Hattori T; Uchiyama T; Yamanishi T; Ito H; Ito K
Auton Neurosci; 2001 Jan; 86(3):208-15. PubMed ID: 11270099
[TBL] [Abstract][Full Text] [Related]
15. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction.
Utomo E; Groen J; Blok BF
Cochrane Database Syst Rev; 2014 May; 2014(5):CD004927. PubMed ID: 24859260
[TBL] [Abstract][Full Text] [Related]
16. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity.
Kuo HC
Urology; 2003 Mar; 61(3):550-4. PubMed ID: 12639645
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment.
Rovner E; Kohan A; Chartier-Kastler E; Jünemann KP; Del Popolo G; Herschorn S; Joshi M; Magyar A; Nitti V
J Urol; 2016 Sep; 196(3):801-8. PubMed ID: 27091236
[TBL] [Abstract][Full Text] [Related]
18. Predictive Factors for a Successful Treatment Outcome in Patients with Different Voiding Dysfunction Subtypes Who Received Urethral Sphincter Botulinum Injection.
Kao YL; Ou YC; Tsai KJ; Kuo HC
Toxins (Basel); 2022 Dec; 14(12):. PubMed ID: 36548774
[TBL] [Abstract][Full Text] [Related]
19. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
[TBL] [Abstract][Full Text] [Related]
20. Real-Life Treatment Outcome of Botulinum Toxin A Injection on Overactive Bladder and Voiding Dysfunction in Patients with Central Nervous System Lesions.
Jiang YH; Jhang JF; Chen SF; Kuo HC
Toxins (Basel); 2024 Mar; 16(3):. PubMed ID: 38535789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
